A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence

Disease (cancer type)

Skin Cancer

Contact information

  • North Florida / Jacksonville: Rhonda Calhoun (904) 427-1217

Patient Selection Criteria

Ages Eligible for Study: 18 Years to 80 Years (Adult, Senior) Genders Eligible for Study: Both Accepts Healthy Volunteers: No Criteria Inclusion Criteria: •Histologically confirmed Stage IIb, IIc, III melanoma •Surgical resection within 90 days of first dosing •Persons with positive sentinel nodes must have a complete lymphadenectomy •ECOG performance status 0 or 1 Exclusion Criteria: •Any prior melanoma treatment other than surgery or regional irradiation •Diagnosis of non-cutaneous melanoma or melanoma with unknown primary origin •Use of biologic response modifiers within 60 days of first dosing •Subjects with history of other malignancy within past 5 years (with exceptions)

Research sponsor

Polynoma LLC

Reference ID#

MAVIS Melanoma


  • Florida

Linked Physicians

To top